1.3.1.48: 13,14-dehydro-15-oxoprostaglandin 13-reductase

This is an abbreviated version!
For detailed information about 13,14-dehydro-15-oxoprostaglandin 13-reductase, go to the full flat file.

Word Map on EC 1.3.1.48

Reaction

11alpha-hydroxy-9,15-dioxoprostanoate
+
NAD(P)+
=
(13E)-11alpha-hydroxy-9,15-dioxoprost-13-enoate
+
NAD(P)H
+
H+

Synonyms

15-hydroxyprostaglandin dehydrogenase, 15-keto-PG reductase, 15-ketoprostaglandin DELTA-13-reductase, 15-ketoprostaglandin DELTA13-reductase, 15-ketoprostaglandinDELTA13-reductase, 15-oxoprostaglandin 13-oxidase, 15-oxoprostaglandin 13-reductase, 15-oxoprostaglandin DELTA13-reductase, 15-oxoprostaglandin-DELTA13-reductase, 15-PGDH, Ad-PGR, bifunctional leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase, bifunctional LTB4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase, DELTA13-15-ketoprostaglandin reductase, leukotriene B4 12-hydroxydehydrogenase/15-ketoprostaglandin 13-reductase, leukotriene B4 dehydrogenase, leukotriene B4-12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase, LTB4 12-HD/PGR, LTBDH/PGR, NAD(P)H-dependent alkenal/one oxidoreductase, PG reductase, PGR, PGR-2, PGR1, prostaglandin 13-reductase, prostaglandin DELTA13-reductase, prostaglandin reductase 1, reductase, 15-oxo-DELTA13-prostaglandin

ECTree

     1 Oxidoreductases
         1.3 Acting on the CH-CH group of donors
             1.3.1 With NAD+ or NADP+ as acceptor
                1.3.1.48 13,14-dehydro-15-oxoprostaglandin 13-reductase

General Information

General Information on EC 1.3.1.48 - 13,14-dehydro-15-oxoprostaglandin 13-reductase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
evolution
the three human PG reductases are zinc-independent members of the medium-chain dehydrogenase/reductase (MDR) superfamily
metabolism
prostaglandins are lipid compounds derived from arachidonic acid by the action of cyclooxygenases, acting locally as messenger molecules in a wide variety of physiological processes, such as inflammation, cell survival, apoptosis, smooth muscle contraction, adipocyte differentiation, vasodilation and platelet aggregation inhibition. In the inactivating pathway of prostaglandins, the first metabolic intermediates are 15-keto-prostaglandins, which are further converted into 13,14-dihydro-15-keto-prostaglandins by different enzymes having 15-keto-prostaglandin reductase activity
physiological function
-
prostaglandin E2, PGE2, has a short half-life in vivo because is rapidly oxidized to 15-ketoprostaglandins by the cytosolic enzyme 15-PGDH. PGE2 acts through EP2 and EP4 receptors to mediate regeneration and hematopoietic stem cell development via the Wnt signaling pathway. Wnt activation in stem cells requires PGE2, and the PGE2/Wnt interaction is a master regulator of vertebrate regeneration and recovery. PGE2 regulates vertebrate hematopoietic stem cell induction and engraftment